Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

The Alzheimer's Disease space is highly volatile, with stock prices reacting to positive or negative data from other companies in the sector. Cassava Sciences, Inc. experienced a correction after initial gains, highlighting the need for caution in the Alzheimer's space. Concerns were raised about the validity of Cassava's phase 2 trial, including participant bias, dropout bias, and the lack of a p-value.

Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet

A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzheimer's disease drug.

Why Shares of Cassava Sciences Soared This Week

AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A live webcast and archived replay will also be available.

Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY

Cassava Sciences (NASDAQ: SAVA) stock price has crawled back this week after the company moved on with its Alzheimer's drug trial. The shares, which have been in a freefall for months, jumped to a high of $19.50, a few points above this month's low of $16.45.

Cassava Sciences (SAVA) stock price forms a bullish pattern: is it a buy?

AUSTIN, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pivotal Phase 3 clinical trial. Eight hundred four (804) Alzheimer's patients are enrolled in this 12-month trial. A second Phase 3 clinical trial with a target enrollment of approximately 1,100 patients is expected to complete patient enrollment in Q4 2023. Both on-going Phase 3 clinical trials are evaluating the safety and efficacy of oral simufilam in patients with Alzheimer's disease dementia.

Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer's Disease

AUSTIN, Texas, Sept. 18, 2023 (GLOBE NEWSWIRE) --  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced a positive interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer's disease. A routine, scheduled meeting of a Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences' Phase 3 studies of simufilam continue as planned, without modification.

Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer's Disease

American Superconductor

BlackBerry

Lithium Americas Corp

Moderna

Super Micro Computer

SoFi Technologies

Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. In fact, considering GME's continued declines, and AMC's capitulation in recent weeks, you may think that the meme stock phenomenon has completely gone the way of the dodo.

The 7 Best Meme Stocks to Buy Now: September 2023

AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the publication of new research that confirms the biological activity of simufilam. Simufilam is Cassava Sciences' novel drug candidate for people with Alzheimer's disease dementia and is currently under evaluation in a pair of global Phase 3 clinical trials.

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer's Disease

AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that it has been invited to present at the following investor conferences.

Cassava Sciences Invited to Present in Four Upcoming Investor Conferences

Apple

Atlanta Braves Holdings Inc

Energy Transfer LP Unit

Liberty Media Corp-Liberty Formula One

Globalstar

Liberty Media Corp-Liberty SiriusXM

Lyft

QUALCOMM

Sirius XM Holdings Inc

Workday

Energy Transfer LP, Cassava Sciences, and PENN Entertainment Inc. were discussed in last week's insider trades update. CEO of Sirius XM Holdings Inc., Jennifer Witz, purchased 250,000 shares for over $1 million. Lyft, Inc. shares have risen nearly 20% since the introduction of new CEO David Risher in April, and insiders like the stock also.

Week Of 08/28 Notable Insider Buys

Penn Entertainment

Energy Transfer LP CEO and Executive Vice President make significant insider purchases, with the CEO's YTD purchases totaling around $115 million. Cassava Sciences directors purchase shares amidst discussions of a potential short squeeze, despite the company's net losses and investigations. PENN Entertainment director buys shares following the company's $2 billion agreement with ESPN, despite a slight dip in share prices.

Week Of 08/21 Notable Insider Buys

Cassava Sciences (NASDAQ: SAVA ) stock jumped 5% overnight after director Richard Barry revealed he acquired shares on behalf of his trust. Barry paid $16.80 for each of the 1,905 shares on Aug. 21.

Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock

Cassava Sciences' core AD treatment candidate simufilam slowed cognitive decline compared to placebo (albeit non-significantly) and stabilized cognition over 18 months in mild patients, which is unprecedented compared to historical data. However, I am concerned about lack of statistical significance, red flags in SAVA reports of top-line results, questionable validity of comparisons with historical data, ongoing litigations and limited cash runaway. Despite the promising data, I give SAVA a "Hold" recommendation considering uncertainty about the outcome of phase 3 studies, several red flags, and likely absence of short-term catalysts.

Cassava Sciences: CMS Data Promising But Many Red Flags Remain; Hold

Cassava Sciences (NASDAQ: SAVA) stock price sell-off intensified as the recent momentum faded. SAVA shares plunged to a low of $18.30 on Monday, the lowest level since August 8th of this year.

As Cassava Sciences (SAVA) stock slips, is it safe to buy the dip?

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2023. Net loss was $26.4 million, or $0.63 per share, compared to a net loss of $19.3 million, or $0.48 per share, for the same period in 2022. Net cash used in operations was $33.2 million during the first half of 2023. Net cash use in second half 2023 is expected to be $40 to $50 million, driven primarily by expenses for our clinical program in Alzheimer's disease.

Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates

Ginkgo Bioworks Holdings

MannKind

The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the sector.

Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now

Amyris

Novavax

Ocugen, Inc.

VBI Vaccines

Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.

7 Biotech Stocks to Sell in July

Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials

Cassava stock crashed in reaction to top-line data from a Phase 2 trial. Both treatment and placebo groups showed little decline on a cognitive test.

Why The Market Is Likely Wrong About Cassava Sciences, Again

Cassava Sciences (NASDAQ: SAVA ) stock is well in the red today despite announcing Phase 3 results for its Alzheimer's treatment. Indeed, SAVA stock is down more than 10% at the time of this writing on relatively lukewarm clinical trial news.

Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results

Cassava Sciences' Alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but the results were not statistically significant, raising doubts about its efficacy. Despite a cash reserve of $187.5 million, Cassava's Q1 2023 net loss was $24.3 million, mainly due to increased patient enrollment costs for Phase 3 trials and other simufilam studies. Despite promising results, I maintain my "Strong Sell" recommendation for SAVA stock due to concerns about financial sustainability and the historically high failure rates of Alzheimer's drugs.

Cassava Sciences: Why Market Skepticism Persists Despite Positive Findings On Simufilam

Simufilam slowed cognitive decline by 38% compared to a placebo after six months for patients with mild to moderate Alzheimer's disease. Cassava Sciences has been the target of shareholder lawsuits, short-seller reports, and government inquiries.

Why Shares of Cassava Sciences Are Dropping Wednesday

AUSTIN, Texas, July 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced top-line clinical results from its Cognition Maintenance Study (CMS). The CMS is a small proof-of-concept study designed to demonstrate the effects of drug versus placebo in a randomized withdrawal trial design. The study enrolled 157 patients with mild-to-moderate Alzheimer's disease, a more advanced and difficult-to-treat stage of disease.

Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer's Disease

AUSTIN, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the publication of a new paper in Frontiers in Aging, a peer-reviewed journal focused on age-related scientific research. The new paper examined the effects of simufilam on mTOR. Simufilam is Cassava Sciences' novel, oral drug candidate currently in Phase 3 clinical testing in patients with mild-to-moderate Alzheimer's disease dementia.

New Research Shows Simufilam Suppresses Overactive mTOR

AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal. This article reviews certain receptor-protein interactions, including an overview of basic science supporting simufilam. Simufilam is Cassava Sciences' oral investigational drug candidate that is currently in Phase 3 clinical trials in patients with mild-to-moderate Alzheimer's disease dementia.

News for Cassava Sciences Inc Stock (SAVA)